Table 8.
Combinations of miRNAs in the diagnosis of BC
| Combinations of miRNA | SN [%] | SP [%] | AUC | References |
|---|---|---|---|---|
| miR-1246+miR-206+miR-24+miR-373 | 98.0 | 96.0 | 0.992 | Jang et al. (2021) |
| miR-145-5p+miR-191-5p (miR-222-3p normalization) | 94.3 | 100 | 0.984 | Ashirbekov et al. (2020) |
| let-7b-5p+miR-122-5p+miR-146b-5p+miR-210-3p+miR-215-5p (external validation set) | 94.4 | 88.9 | 0.978 | Li et al. (2019) |
| miR-92a-3p+miR-23b-3p+miR-191-5p | 89.2 | 96 | 0.977 | Sharifi et al. (2022) |
| miR-1246+miR-1307-3p+miR-4634+miR-6861-5p+miR-6875-5p (in the test cohort) | 97.3 | 82.9 | 0.971 | Shimomura et al. (2016) |
| miR-145+miR-425-5p+miR-139-5p+miR-130a | 97 | 91 | 0.97 | Itani et al. (2021) |
| miR-1246+miR-202+miR-21+miR-219B (patients under the age of 50) | 85.29 | 93.33 | 0.961 | Jang et al. (2021) |
| miR-185-5p+miR-362-5p | 92.65 | 92.31 | 0.957 | Zhang et al. (2021) |
| miR-451+miR-148a+miR-27a+miR-30b | 94.7 | 82.8 | 0.953 | Luo et al. (2014) |
| miR-10b-5p+miR-133a-3p+miR-155-3p+miR-195-5p+miR-195-3p | 79 | 100 | 0.948 | Jing et al. (2024) |
| c-miR-16+c-miR-21+c-miR-155+c-miR-195 | 88.89 | 86.67 | 0.936 | Fan et al. (2018) |
| miR-21+miR-155+miR-365 | 85.71 | 85.72 | 0.918 | Han et al. (2017) |
| miR-199a+miR-29c+miR-424 | 77.2 | 88.9 | 0.905 | Zhang et al. (2015) |
| BC vs normal hsa-miR-324-3p/hsa-miR-382-5p, hsa-miR-21-3p/hsa-miR-324-3p, hsa-miR-30a-5p/hsa-miR-30e-5p, hsa-miR-221-3p/hsa-miR-324-3p | 89.0 | 92.5 | 0.901 | Fang et al. 2018) |
| BC vs benign hsa-miR-30a-5p/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-574-5p, hsa-miR-21-3p/hsa-miR-221-3p, hsa-miR-221-3p/hsa-miR-30a-5p | 88.1 | 77.5 | 0.901 | |
| BC vs control (normal+benign) hsa-miR-30e-5p/hsa-miR-382-5p, hsa-miR-221-3p/hsa-miR-324-3p, hsa-miR-30a-5p/hsa-miR-382-5p, hsa-miR-152/hsa-miR-382-5p, hsa-miR-192-5p/hsa-miR-382-5p | 71.7 | 78.2 | 0.820 | |
| miR-195+miR-210+miR-21+miR-16 | 71.4 | 100 | 0.898 | Miranda et al. (2024) |
| miR-21-3p+miR-21-5p+miR-99a-5p | 97.9 | 73.5 | 0.895 | Yu et al. (2018) |
| EV-miRNAs: miR-9+miR-16+miR-21+miR-429 | 96.8 | 80 | 0.88 | Kim et al. (2021) |
| EV-miRNAs: miR-142-5p+miR-320a+miR-4433b-5p (BC patients vs healthy controls) | 93.33 | 68.75 | 0.8387 | Ozawa et al. (2020) |
| (luminal A vs healthy controls) | 100 | 93.8 | 0.9410 | |
| miR-30b-5p+miR-99a-5p | 57.4 | 87.54 | 0.77 | Adam-Artigues et al. (2021) |
| in stage I BC | 82.35 | 87.54 | 0.9273 | |
| miR-210+miR-152 | 83.33 | 68.0 | 0.754 | Lopes et al. (2021) |
| miR-23a-3p+miR-130a-5p+miR-144-3p+miR-148a-3p+miR-152-3p | 86.5 | 45.9 | 0.699 | Li et al. (2020) |
| miR-15a+miR-18a+miR-107+miR-133a+miR-139-5p+miR-143+miR-145+miR-365+miR-425 | 83.3 | 41.2 | 0.665 | Kodahl et al. (2014) |